Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03413722 · ClinicalTrials.gov registry record
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
A clinical trial, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT03413722 is a clinical trial that has completed, run by University of Kansas Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT03413722 has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.
Interventions
- DRUG Everolimus
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2022-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03413722
The ClinicalTrials.gov registry entry for NCT03413722 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT03413722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03413722 about?
NCT03413722 is a clinical study titled "Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus". The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.
What is the current status of trial NCT03413722?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2018-02-01. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT03413722?
The interventions under investigation include: Everolimus (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT03413722?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.